scholarly journals Delivery of modified mRNA encoding vesicular stomatitis virus matrix protein for colon cancer gene therapy

RSC Advances ◽  
2018 ◽  
Vol 8 (22) ◽  
pp. 12104-12115 ◽  
Author(s):  
Ke Men ◽  
Rui Zhang ◽  
Xueyan Zhang ◽  
Rong Huang ◽  
Guonian Zhu ◽  
...  

Liposome–protamine complex delivered VSVMP mRNA efficiently inhibits C26 colon carcinoma with safety, providing an alternative strategy for non-viral gene therapy.

2008 ◽  
Vol 22 (12) ◽  
pp. 4272-4280 ◽  
Author(s):  
Ju‐mei Zhao ◽  
Yan‐jun Wen ◽  
Qiu Li ◽  
Yong‐sheng Wang ◽  
Hong‐bo Wu ◽  
...  

RSC Advances ◽  
2018 ◽  
Vol 8 (30) ◽  
pp. 16537-16548 ◽  
Author(s):  
Ke Men ◽  
Rong Huang ◽  
Xueyan Zhang ◽  
Rui Zhang ◽  
Yuanfa Zhang ◽  
...  

Cationic DMP micelle delivered interleukin-22BP gene efficiently inhibits colon carcinoma growth, providing a novel strategy for cancer gene therapy.


2006 ◽  
Vol 175 (4S) ◽  
pp. 139-140
Author(s):  
Seth A. Strope ◽  
Jian Pu ◽  
Sherwin Zargaroff ◽  
Savio L. Woo ◽  
Simon J. Hall

2018 ◽  
Vol 14 (7) ◽  
pp. 1239-1251 ◽  
Author(s):  
Rui Zhang ◽  
Ke Men ◽  
Xueyan Zhang ◽  
Rong Huang ◽  
Yaomei Tian ◽  
...  

2013 ◽  
Vol 43 (5) ◽  
pp. 1618-1626 ◽  
Author(s):  
YAO WU ◽  
ZHENG GUO ◽  
DI ZHANG ◽  
WENJING ZHANG ◽  
QINGQING YAN ◽  
...  

1998 ◽  
Vol 72 (10) ◽  
pp. 8413-8419 ◽  
Author(s):  
Maryam Ahmed ◽  
Douglas S. Lyles

ABSTRACT The matrix (M) protein of vesicular stomatitis virus (VSV) functions in virus assembly and inhibits host-directed gene expression independently of other viral components. Experiments in this study were carried out to determine the ability of M protein to inhibit transcription directed by each of the three host RNA polymerases (RNA polymerase I [RNAPI], RNAPII, and RNAPIII). The effects of wild-type (wt) VSV, v6 (a VSV mutant isolated from persistently infected cells), and tsO82 viruses on poly(A)+ and poly(A)− RNA synthesis were measured by incorporation of [3H]uridine. v6 andtsO82 viruses, which contain M-gene mutations, had a decreased ability to inhibit synthesis of both poly(A)+ and poly(A)− RNA. Nuclear runoff analysis showed that VSV inhibited transcription of 18S rRNA and α-tubulin genes, which was dependent on RNAPI and RNAPII, respectively, but infection with wt virus enhanced transcription of 5S rRNA by RNAPIII. The effect of M protein alone on transcription by RNAPI-, RNAPII-, and RNAPIII-dependent promoters was measured by cotransfection assays. M protein inhibited transcription from RNAPI- and RNAPII-dependent promoters in the absence of other viral gene products. RNAPIII-dependent transcription of the adenovirus VA promoters was also inhibited by M protein. However, as observed during wt VSV infection, M protein enhanced endogenous 5S rRNA transcription, indicating that the inhibition of transcription by RNAPIII was dependent on the nature of the promoter.


2020 ◽  
Vol 16 (10) ◽  
pp. 1518-1529
Author(s):  
Tingting Yang ◽  
Ting Luo ◽  
Hongjun Guo ◽  
Yuzhu Hu ◽  
Yunzhu Lin ◽  
...  

Gene therapy has been widely studied in colon cancer treatment. However, effective delivery of genes is a limitation for clinical applications. In the research, DOATP/mPEG-PLA-mPEG (DPLP) nanoparticles carrying the vesicular stomatitis virus matrix protein plasmid (pVSVMP) was used for colon cancer therapy, resulting in high transfection efficiency and expression efficiency in CT26 cells. Moreover, the DPLP-pVSVMP complex was provide with apoptosis induction and proliferation suppression of CT26 cells in vitro and can efficiently inhibit tumor growth in murine colon cancer model by inducing apoptosis, suppressing proliferation and angiogenesis. These results suggest that DPLP nanoparticles delivering pVSVMP might be a latent therapeutic avenue for colon cancer.


2019 ◽  
Vol 14 (1) ◽  
Author(s):  
Yongping Lu ◽  
Lei Zhong ◽  
Zhongliang Jiang ◽  
Haixia Pan ◽  
Yuanfa Zhang ◽  
...  

2020 ◽  
Vol 16 (8) ◽  
pp. 1183-1195
Author(s):  
Jingming Zhai ◽  
Yanliang Zhu ◽  
Jiangbo Liu ◽  
Junling An ◽  
Yingjie Yu ◽  
...  

Colorectal carcinoma is a complex disease accounting for adenoma tumors and an aggressive phenotype, and the third leading cause of cancer death. In the past decades, miRNAs have been associated with molecular pathways of cancer and other diseases. The dysregulated miRNAs play an inhibitory or promoting role in tumorigenesis. Therefore, restoration of tumor-suppressed microRNAs (miRNA) may offer novel therapeutic approaches for cancer treatment. Nevertheless, the poor bioavailability of miRNA due to their rapid enzymatic degradation is a critical barrier in cancer gene therapy. To overcome this dilemma, we designed disulfide cross-linking micelles (DCM) nanocarrier for delivery of miR-145 to colon cancer cells and investigated its therapeutic efficacy in vitro and in vivo. Results indicated that the presence of DCM nanocarrier loaded with miR-145 enhanced selective delivery of miR-145 and facilitated cellular uptake, significantly up-regulating miR-145 expression in HCT-116 cell lines. Consequently, the cell proliferation was inhibited by arresting cell cycle at the G1 phase. Further, apoptosis of HCT-116 cells treated with miR-145 complex nanoparticles may be via downregulation of oncogenes MYC and FSCN1, predicting regulatory targets for miR-145. These results pave the way for further investigations into the potential of miR-145 complex nanocarrier for cancer gene therapy.


Sign in / Sign up

Export Citation Format

Share Document